Late clinical failure associated with cytochrome b codon 268 mutation during treatment of falciparum malaria with atovaquone–proguanil in traveller returning from Congo

Late clinical failure associated with cytochrome b codon 268 mutation during treatment of falciparum malaria with atovaquone–proguanil in traveller returning from Congo

Abstract Background The drug combination atovaquone–proguanil, is recommended for treatment of uncomplicated falciparum malaria in France. Despite high efficacy, atovaquone–proguanil treatment failures have been reported. Resistance to cycloguanil, the active metabolite of proguanil, is conferred by...

Full description

Bibliographic Details
Main Authors: Laurencie Massamba, Marylin Madamet, Nicolas Benoit, Alicia Chevalier, Isabelle Fonta, Véronique Mondain, Pierre-Yves Jeandel, Rémy Amalvict, Pascal Delaunay, Joel Mosnier, Pierre Marty, Christelle Pomares, Bruno Pradines
Format: Article
Language:English
Published: BMC 2020-01-01
Series:Malaria Journal
Subjects:
Malaria
Plasmodium falciparum
Anti-malarial drug
Resistance
In vitro
Atovaquone
Online Access:https://doi.org/10.1186/s12936-020-3126-y

Internet

https://doi.org/10.1186/s12936-020-3126-y

Similar Items